Navigation Links
Angeion Corporation Reports First Quarter Fiscal Year 2012 Operating Results
Date:2/28/2012

ally impacted revenues in the first quarter of fiscal 2012 with a 26% decrease in total international sales from last year's first quarter. We continue to believe that international markets will be a significant contributor in the coming years and we are dedicated to strengthening our distribution capabilities in those markets as economic conditions improve."

Dr. Lehman continued, "We are committed to developing new products and refreshing our existing product lines so that they can be produced in the most cost-efficient manner possible, leading to enhanced margins, and giving us the ability to enter into new markets. We are pleased to have recently introduced to our customers worldwide our new RTD™ (Real-Time Diffusion™) MultiGas Technology™. This proprietary technology platform and real-time sensor quality assurance provides accurate and immediate results, and eliminates the need for repeat tests. The addition of RTD to our product family will provide access to markets from which Angeion may have been previously excluded. This ability to better serve our existing markets and enter new markets represents the new product development model that we expect to execute. We are committed to becoming an industry leader in efficient manufacturing practices and innovative diagnostic solutions."

"As we move through fiscal year 2012, we will commence a number of initiatives, including rebranding the company and leveraging the MedGraphics name to more fully capitalize on the favorable brand equity that we have developed over the years. We look to solidify the identity of the company with that of our products in the minds of our customers and the national investment community as well. Our strong working capital position will facilitate plans to expand and advance our product lines via in-house development as well as participating in joint venture opportunities, and opportunistic and strategic acquisitions. With the business on a more stable footi
'/>"/>

SOURCE Angeion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Angeion Corporation to Report Third Quarter Fiscal Year 2011 Financial Results on Thursday, September 1, 2011
2. Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results
3. Angeion Corporation to Report Fourth Quarter and Fiscal Year 2011 Financial Results on Friday, December 16, 2011
4. Angeion Corporation Reports Fourth Quarter and Fiscal Year 2011 Operating Results
5. Angeion Corporation to Report First Quarter Fiscal 2012 Financial Results on Tuesday, February 28, 2012
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
10. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
11. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Richmond Pharmacology is ... with a worldwide reputation for excellence in clinical ... in peer reviewed medical journals. Its officers are ... in discussions about rules for transparency and publication ... http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is conducted ...
(Date:5/21/2015)... Research and Markets ... of the "North American Joint Reconstruction ... Elbow Replacement, Hip Replacement, Knee Replacement, Shoulder ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... at $4,470.9 million in 2014 and is ...
(Date:5/21/2015)... May 21, 2015 Research ... addition of the "Market Assessment of Respiratory ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... respiratory imaging diagnostics market in the ... . The service provides detailed analysis of ...
Breaking Medicine Technology:North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... Medical, Inc. (OTCBB: HASC), www.mysouthernmed.com , a managed ... Mississippi, announced the launch of a newly redesigned  web ... Vans of America ( www.WCvans.com ). ... more customer friendly.   MobilityFreedom.com now provides an ...
... BRISBANE, Calif., July 18, 2011 SARcode Bioscience, ... completion of a $44 million Series B private ... Sofinnova Ventures and was augmented by the additional ... Partners and Clarus Venture Partners. ...
Cached Medicine Technology:HASCO Medical Announces New Redesigned Websites for Mobility Freedom and Wheelchair Vans of America 2SARcode Bioscience Completes $44 Million Series B Financing 2SARcode Bioscience Completes $44 Million Series B Financing 3SARcode Bioscience Completes $44 Million Series B Financing 4
(Date:5/22/2015)... May 22, 2015 The American College ... events in June. They will hold a webinar on ... a two-day class on Classical Chinese Medicine. , Webinar ... Dr. Steve Given, the Dean of Clinical Education, will ... new First Professional Doctorate program. ACTCM is currently developing ...
(Date:5/22/2015)... East Liverpool, OH (PRWEB) May 22, 2015 ... today announced that Kyle Johnson, the health system’s Chief ... pursue other interests. Johnson has served as the company ... announced Wesley West will be joining the health system ... operations on an interim basis, while the Board of ...
(Date:5/22/2015)... Halifax, NS (PRWEB) May 22, 2015 ... into a sale agreement with US-based health brand Nature’s ... Ascenta Skin brand. Retention of Ascenta Skin is an ... St-Onge is excited about this opportunity to further develop ... industry. , Ascenta Skin is a breakthrough, anti-aging ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Combination ... treatment option for chronic obstructive pulmonary disorder (COPD) ... plc and AstraZeneca plc as well as Germany’s ... share and position. But will market payers, clinicians ... already well-entrenched products to completely new ones? , ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... of Cincinnati (UC) researcher will receive $2.5 million over ... (NIDA) to support his work on a potential immunotherapy ... in the psychiatry and behavioral neuroscience department, is one ... Awards for Innovative Medication Development Research. Award winners receive ...
... targeted therapies can reduce tumors rapidly. However, not all ... do often develop resistance over time. Looking for a ... Fox Chase Cancer Center hypothesized that hitting already weakened ... thembut only if it was the right second agent. ...
... be improved with training and the improvement is marked ... University study. A research team led by ... of the brain that controls impulsive behavior and the ... findings could have a significant impact on the diagnosis ...
... By Steven Reinberg HealthDay Reporter , ... finds it,s safe to take the blood thinner Plavix ... that said the combination compromised Plavix,s effectiveness. "We ... and proton-pump inhibitors," said lead researcher Dr. Mette Charlot ...
... tenth anniversary of the Jackson Heart Study (JHS) will ... JHS is the largest study in history to investigate ... lung disease, stroke, diabetes, and other important diseases in ... among African-Americans than among whites in the United States. ...
... CHAPEL HILL, N.C. Scientists from University of North Carolina ... Inc. announced today findings from a large clinical study ... the worsening of osteoarthritis. The study, which was ... with X-ray evidence of knee osteoarthritis who inherited a ...
Cached Medicine News:Health News:Researcher wins $2.5 million award from National Institute on Drug Abuse 2Health News:'Synthetic lethality' strategy improves molecularly targeted cancer therapy 2Health News:'Synthetic lethality' strategy improves molecularly targeted cancer therapy 3Health News:Queen's University researchers locate impulse control center in brain 2Health News:Plavix, Heartburn Drug Safe to Take Together: Study 2Health News:NIH celebrates 10 years of research into health disparities 2Health News:UNC researchers identify genetic patterns that may predict osteoarthritis 2Health News:UNC researchers identify genetic patterns that may predict osteoarthritis 3
... respiration and ventilation., ,The Capnomac Ultima is ... monitors available. The Capnomac Ultima is available in ... measure the essential airway gas parameters, CO 2 ... O easily and reliability. The Capnomac Ultima also ...
Adhesive discs sold on rolls of 100, 250, or 1000 each. Manufactured from non-latex medical grade adhesives & material. One size fits all chest pieces....
For accurately monitoring core temperature and heart and breath sounds as well as for gastric suctioning....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: